GENEDX HOLDINGS CORP
WGSNASDAQTrading Snapshot
- Day Range
- $81.30 – $83.58
- 52-Week Range
- $32.21 – $170.87
- Volume
- $5.26B
- Avg Volume
- $5.23B
- Shares Outstanding
- 29.8M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $428M
- Last Q Revenue
- $114M
- P/E Ratio
- -22.6
- P/S Ratio
- 5.4x
- EPS (TTM)
- $-3.58
- Dividend Yield
- 0.00%
Why Investors Own WGS
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GENEDX HOLDINGS CORP
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance.
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90
Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target
BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.
GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ...
GeneDx returns to profitability ahead of schedule, driven by 32% exome and genome volume growth and expanded commercial coverage.
GeneDx Holdings (NASDAQ:WGS) Beats Q2 Revenue Estimates and Swings to Adjusted Profit
GeneDx beats Q2 revenue estimates, swings to surprise adjusted profit, and lifts outlook; shares rise in after-hours trading.
GeneDx Q2 Earnings Call Highlights
GeneDx (NASDAQ:WGS) reported second-quarter revenue of $114.4 million, above its prior guidance, as exome and genome testing volume reached a quarterly record of more than 30,000 tests. The company also returned to adjusted profitability one quarter earlier than previously expected, while maintainin